Xeris Biopharma Holdings, Inc.

How big is Xeris Biopharma Holdings, Inc.?

As of Jun 18, Xeris Biopharma Holdings, Inc. has a market capitalization of $727.10 million, with net sales of $222.55 million and a net profit of -$45.08 million over the last four quarters.

As of Jun 18, Xeris Biopharma Holdings, Inc. has a market capitalization of 727.10 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 222.55 million, while the sum of net profit for the same period is -45.08 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at -29.61 million and total assets at 329.15 million.

What does Xeris Biopharma Holdings, Inc. do?

Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company focused on developing injectable and infusible drug formulations. As of March 2025, it reported net sales of $60 million and a net loss of $9 million, with a market cap of $727.10 million.

Overview:<BR>Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company engaged in developing and commercializing injectable and infusible drug formulations within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 60 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 727.10 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -5.05<BR>- Return on Equity: 131.24%<BR>- Price to Book: -20.70<BR><BR>Contact Details:<BR>- Address: 180 NORTH LASALLE STREET, SUITE 1600, CHICAGO IL: 60601<BR>- Tel: 1 512 4982670<BR>- Fax: 1 302 6555049<BR>- Website: https://www.xerispharma.com/

Should I buy, sell or hold Xeris Biopharma Holdings, Inc.?

Who are in the management team of Xeris Biopharma Holdings, Inc.?

As of March 2022, the management team of Xeris Biopharma Holdings, Inc. includes Paul Edick as Chairman and CEO, with John Schmid as Lead Independent Director and independent directors BJ Bormann, Dawn Halkuff, Marla Persky, and Jeffrey Sherman.

As of March 2022, the management team of Xeris Biopharma Holdings, Inc. includes Mr. Paul Edick, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, the Board of Directors features Mr. John Schmid as the Lead Independent Director, along with independent directors Dr. BJ Bormann, Ms. Dawn Halkuff, Ms. Marla Persky, and Dr. Jeffrey Sherman.

Is Xeris Biopharma Holdings, Inc. overvalued or undervalued?

As of August 13, 2018, Xeris Biopharma Holdings, Inc. is considered risky and overvalued due to negative financial metrics, including a Price to Book Value of -20.88 and a P/E ratio of -15.77, despite a strong stock performance of 119.91% over the past year.

As of 13 August 2018, the valuation grade for Xeris Biopharma Holdings, Inc. moved from does not qualify to risky, indicating a significant change in its risk profile. The company is currently assessed as overvalued, given its negative financial metrics. Key ratios include a Price to Book Value of -20.88, an EV to EBIT of -40.50, and an EV to EBITDA of -91.67, all of which highlight the company's struggles in generating positive returns.<BR><BR>In comparison to its peers, Xeris Biopharma's P/E ratio is notably worse at -15.77 compared to uniQure NV at -3.60 and Nuvation Bio, Inc. at -3.21, both of which also fall under the risky category. The company's recent stock performance shows a 119.91% return over the past year, significantly outpacing the S&P 500's 10.26% return, yet this does not mitigate the valuation concerns stemming from its negative earnings and high debt metrics.

Is Xeris Biopharma Holdings, Inc. technically bullish or bearish?

As of August 1, 2025, Xeris Biopharma Holdings, Inc. shows a bullish technical trend, supported by positive MACD and moving averages, despite a bearish weekly RSI and mixed signals, while significantly outperforming the S&P 500 with a year-to-date return of 144.84%.

As of 1 August 2025, the technical trend for Xeris Biopharma Holdings, Inc. has changed from mildly bullish to bullish. The MACD is bullish on both the weekly and monthly time frames, while the Bollinger Bands also indicate a bullish stance in both periods. The daily moving averages are bullish, supporting the overall positive trend. However, the weekly RSI is bearish, which suggests some caution, and the Dow Theory shows no trend on the weekly but is mildly bullish on the monthly. <BR><BR>In terms of performance, Xeris has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 144.84% compared to the S&P 500's 12.22%, and a one-year return of 186.21% versus 17.14%. Overall, the current technical stance is bullish, albeit with some mixed signals in the indicators.